Brivaracetam/Brivaracetam price and availability of domestic generic drugs

Brivaracetam is an innovative anti-epileptic drug widely used to control partial epileptic seizures. It originated in Europe and has been approved and put into use in many countries such as Europe, the United States, and Japan. However, in China, the original research product of brivaracetam has not yet been officially launched, and the market mainly comes from domestically produced generic drugs. It is worth noting that despite entering the market as a generic drug, the price of brivaracetam is still relatively high, a phenomenon that has aroused widespread discussion among patients and clinicians.

The original research brivaracetam was developed byUCB Company. It has high selectivity and good safety. Its efficient neuron stabilizing mechanism has quickly gained recognition in the European and American markets. Since its original research has not yet been approved for marketing in China, a few domestic pharmaceutical companies currently produce generic versions for clinical use. Limited by factors such as insufficient market competition, R&D cost transfer, approval procedures and supply chain complexity, the price of generic drugs of Brivaracetam has not been significantly reduced due to its "non-original research" status. On the contrary, in some places, the price is even higher than that of similar marketed original drugs such as levetiracetam.

In addition, although generic drugs have passed national review in terms of efficacy consistency evaluation, the accumulation of actual clinical experience is relatively limited, and doctors are still cautious when choosing brivaracetam treatment. In the future, as more pharmaceutical companies enter the market, if the original drug can be officially approved, and the medical insurance catalog is dynamically adjusted, the price of brivaracetam is expected to become more reasonable, thereby expanding its accessibility and patient compliance in the treatment of epilepsy. In the long term, clinicians and patients' expectations for brivaracetam not only lie in the stability of its efficacy, but also in its becoming a safe, affordable, and suitable new treatment option for Chinese epilepsy patients.

Reference materials:https://www.briviact.com/